Wall Street Analysts See a 104.08 percent Upside in Foghorn Therapeutics Can the Stock Really Move This High?
| FHTX Stock | USD 7.79 0.27 3.59% |
Slightly above 70 percent of all Foghorn Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Foghorn Therapeutics suggests that a large number of traders are confidant. Foghorn Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Foghorn Therapeutics' earnings reports, geopolitical events, and overall market trends.
Foghorn |
The mean of analysts price targets for Foghorn Therapeutics points to a 104.1 percent upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read at zacks.com
 |
Foghorn Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Foghorn Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Foghorn Therapeutics Fundamental Analysis
We analyze Foghorn Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Foghorn Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Foghorn Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Foghorn Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Foghorn Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Foghorn Therapeutics stock to make a market-neutral strategy. Peer analysis of Foghorn Therapeutics could also be used in its relative valuation, which is a method of valuing Foghorn Therapeutics by comparing valuation metrics with similar companies.
Peers
Foghorn Therapeutics Related Equities
| MCRB | Seres Therapeutics | 4.55 | ||||
| SCPH | Scpharmaceuticals | 3.89 | ||||
| MIST | Milestone Pharmaceuticals | 1.08 | ||||
| LUMO | Lumos Pharma | 0.46 | ||||
| IKNA | Ikena Oncology | 1.17 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| TPST | Tempest Therapeutics | 2.08 | ||||
| HCWB | HCW Biologics | 10.71 |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.